D.A. Davidson & CO. decreased its stake in Cambrex Corporation (NYSE:CBM) by 2.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,894 shares of the biotechnology company’s stock after selling 72 shares during the quarter. D.A. Davidson & CO.’s holdings in Cambrex Corporation were worth $172,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Cambrex Corporation by 0.5% in the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after purchasing an additional 20,652 shares during the period. Vanguard Group Inc. boosted its position in shares of Cambrex Corporation by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock valued at $172,799,000 after purchasing an additional 139,010 shares during the period. Congress Asset Management Co. MA boosted its position in shares of Cambrex Corporation by 8.7% in the 2nd quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock valued at $77,497,000 after purchasing an additional 103,900 shares during the period. Clearbridge Investments LLC boosted its position in shares of Cambrex Corporation by 34.8% in the 1st quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock valued at $53,463,000 after purchasing an additional 250,662 shares during the period. Finally, FMR LLC boosted its position in shares of Cambrex Corporation by 78.2% in the 1st quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock valued at $49,494,000 after purchasing an additional 394,638 shares during the period. Institutional investors and hedge funds own 98.28% of the company’s stock.

CBM has been the subject of a number of recent analyst reports. BidaskClub lowered Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $65.67.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at $5,852,185.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the transaction, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,000 shares of company stock valued at $1,574,880. Insiders own 2.48% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/cambrex-corporation-cbm-position-decreased-by-d-a-davidson-co/1617119.html.

Shares of Cambrex Corporation (NYSE CBM) opened at 56.30 on Friday. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The firm’s 50-day moving average price is $52.80 and its 200-day moving average price is $55.36. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 20.51 and a beta of 2.28.

Cambrex Corporation (NYSE:CBM) last posted its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same period in the previous year, the firm earned $0.68 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. On average, equities analysts anticipate that Cambrex Corporation will post $3.08 earnings per share for the current year.

Cambrex Corporation Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.